Research

Confirmed by third party analysis
Pre-clinical study done at Science-in-Action, Israel; Blood analyses performed at the Hebrew University of Jerusalem, Israel

Why is bioavailability important?

DOC-CBD was created to solve the fundamental issues associated with conventional CBD products; low bioavailability, short shelf life, and the wide array of false claims regarding nanotechnology and effectiveness.

Bioavailability

Bioavailability determines the amount a substance is available in the bloodstream when taken orally. Unfortunately, conventional CBD has been shown to have poor oral bioavailability (Mechoulam, 2002) 1which results in the majority of the CBD ingested being excreted in the feces.

Graph Explanation

Notice that ordinary CBD products in orange have very minimal absorption into the bloodstream at 0.5 hours and 2.0 hours compared to DOC-CBD absorption in green has a significant increase absorption at both intervals. 

Graph Explanation

Notice that the ordinary CBD products in orange deteriorate rapidly, whereas the horizontal green line shows that DOC-CBD maintains its integrity in the presence of stomach acid.

Fares Better in the Stomach

DOC-CBD’s patented technology, nextCBD™, retains integrity in the stomach, allowing more of the active ingredient to absorb into the bloodstream. Ordinary CBD products breakdown quickly, and deteriorate into other substances, resulting in a reduced effect.

Proven Results

DOC-CBD’s products are more effective at treating symptoms caused by inflammation due to the increased bioavailability. The same amount of ingredients translates into a better treatment experience.

TNF is one of many cytokine inflammation markers.

 

Graph Explanation

Notice that in preclinical trials ordinary CBD products in orange do not reduce the inflammatory marker TNF, compared to the significant drops in TNF levels after the administration of  DOC-CBD labeled in green. 

We believe that the poor performance of conventional administration of oral CBD is a result of poor bioavailability.

1. Mechoulam R., Parker L. A., Gallily R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11S−19S. 10.1002/j.1552-4604.2002.tb05998.x

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
This product is not for use by or sale to persons under the age of 18. This product should be used only as directed on the label. It should not be used if you are pregnant or nursing. Consult with a physician before use if you have a serious medical condition or use prescription medications. A Doctor’s advice should be sought before using this and any supplemental dietary product. All trademarks and copyrights are property of their respective owners and not affiliated with nor do they endorse this product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Individual weight loss results will vary. By using this site you agree to follow the Privacy Policy and all Terms & Conditions printed on this site. Void Where Prohibited By Law.

The statements made herein have not been evaluated by the US Food and Drug Administration and are not intended for diagnosing, treating, curing or preventing any disease or medical condition. 

Merchant Equipment Store Credit Card Logos